BHVN250516C12500
- 11.00
- 0.000.00%
Biohaven Newsroom
Biohaven Ltd. Shareholders Approve Key Proposals at Meeting
Express News | Shares of Vaccine and Gene Therapy Stocks Are Trading Lower After FDA Commissioner Marty Makary Reportedly Named Vinay Prasad as Director of the Center for Biologics and Research
Express News | 'FDA Names Vinay Prasad as New Head of Vaccines, Biologics'- Bloomberg Law
UBS Adjusts Biohaven Price Target to $40 From $65, Maintains Buy Rating
Biohaven Secures $600m Financing as It Awaits FDA Prodrug Decision
Baird Maintains Biohaven(BHVN.US) With Buy Rating, Cuts Target Price to $57
Why BioHaven Stock Is Soaring Today
$BHVN Stock Is up 7% Today. Here's What We See in Our Data.
Sector Update: Health Care Stocks Mixed Premarket Monday
Stride To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday
Baird Maintains Outperform on Biohaven, Lowers Price Target to $57
Biohaven Analyst Ratings
Express News | Biohaven Ltd - Oberland Capital to Receive Milestone and Royalty Payments on Net Sales of Troriluzole
Express News | Biohaven Announces Investment up to $600 Million by Oberland Capital
Press Release: Biohaven Announces Investment up to $600 Million by Oberland Capital
William Blair Initiates Biohaven(BHVN.US) With Buy Rating
RBC Capital Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $61
Why Biohaven Stock Plummeted by More Than 15% Today
Sector Update: Health Care Stocks Advance in Afternoon Trading
Biohaven Share Price Undervaluing Pipeline Potential, Says RBC Capital